Full metadata record
|dc.description.abstract||Celecoxib, a nonsteroidal anti-inflammatory drug (NSAIDS), is approved specific inhibitor of cyclo-oxygenase-2 (COX-2) to treat rheumatism and osteoarthritis for all ages. Recently, celecoxib is being evaluated for potential treatment of various conditions, such as cancer, which are not exclusive to adults. However, important changes in the disposition of and the response to drugs occur due to rapid growth and development in childhood. Accordingly, because of therapeutic potential of this drug in children, metabolomic study is necessary to determine physiologically and pathologically effects of celecoxib. In this study, metabolic changes in plasma are systemically observed to understand overall metabolism of age-related effect of celecoxib using liquid chromatography mass spectrometry (UPLC-QTOF-MS). 10mg/kg of celecoxib was daily administered to 7 weeks-, and 6 months-aged male SD rats for 4 weeks and their plasma were analyzed. As a result, overall metabolomics changes were more significant in 7 week-aged than 6 moth-aged group after administration. Most of identified metabolites were lipids and showed increasing tendency in both groups. In 7 week-aged group, sphingolipids and cholesterol were significantly increased, whereas glycerophospholipids (especially phosphatidylcholine) were increased in 6 month-aged group along with alteration of a few fatty aclys and biliverdin. These changes of metabolites including lipid molecules might be important markers for drug effects and present alteration of molecular mechanism process after long-term administration. In conclusion, the metabolomic approach of age-related effect of celecoxib provides a contribution of overall metabolism associated with celecoxib in the whole body and critical clues regarding the potential for development, safety and effective prescription of the drug.||-|
|dc.title||Metabolomic approach to determine the age-related effect of celecoxib||-|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.